AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Clinical outcomes after salvage external beam radiotherapy combined with interstitial brachytherapy for locally advanced, recurrent endometrial cancer

Asmara WaheedRobyn BanerjeeTyler MeyerSarah QuirkCorinne DollPhilip McGeachyTien PhanMichael RoumeliotisKevin Martell ( )
Department of Oncology, University of Calgary, Tom Baker Cancer Center, Calgary, Alberta, Canada
Show Author Information

Abstract

Salvage external beam radiation therapy (EBRT) followed by interstitial brachytherapy is commonly used to treat patients with vaginal recurrence of endometrial cancer. The evidence for this is typically limited to case series treating small volumes of disease. For the present study, 12 consecutive patients with locally advanced, biopsy-proven vaginal recurrence after surgically treated endometrial cancer who received salvage EBRT (45 Gy in 25 daily fractions to microscopic disease and 55–57.5 Gy to gross nodal disease) with magnetic resonance-guided interstitial brachytherapy (20–21 Gy in 3 fractions over 2 days) were retrospectively reviewed. The median tumor size of recurrent disease on magnetic resonance imaging was 5 (3–6) cm. Three (25%) tumors involved the bladder wall, three (25%) involved the urethra, and four (33%) extended to the pelvic sidewall. Four (25%) patients had gross nodal disease. On follow-up, no (0%) patient developed local recurrence. One patient (8%) developed nodal recurrence outside of the radiotherapy treatment volume and then distant metastases, and one patient (8%) developed distant metastasis 2.5 years post-treatment and subsequently died from the disease. No (0%) other deaths were reported. Zero patients (0%) developed grade ≥4 bowel or bladder toxicity. These data support EBRT with interstitial brachytherapy using modern techniques for locally advanced, vaginal recurrences of endometrial cancer.

References

1

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

2
Group USCSW. U.S. Cancer Statistics Data Visualizations Tool, based on 2020 submission data (1999-2018):U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute 2021. Accessed May 13, 2022. www.cdc.gov/cancer/dataviz
3

Keys HM, Roberts JA, Brunetto VL. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92: 744-751.

4

Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):631-638.

5

Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(1):16-41.

6

Jeppesen MM, Jensen PT, Gilså Hansen D, Iachina M, Mogensen O. The nature of early-stage endometrial cancer recurrence—A national cohort study. Eur J Cancer. 2016;69: 51-60.

7

Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol. 1999;75(1):99-102.

8

Schmidt AM, Imesch P, Fink D, Egger H. Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients. Int J Gynecol Cancer. 2016;26(4):716-721.

9

Chiantera V, Rossi M, De Iaco P, et al. Morbidity after pelvic exenteration for gynecological malignancies: a retrospective multicentric study of 230 patients. Int J Gynecol Cancer. 2014;24(1):156-164.

10

Kamrava M, Beriwal S, Erickson B, et al. American brachytherapy society recurrent carcinoma of the endometrium task force patterns of care and review of the literature. Brachytherapy. 2017;16(6):1129-1143.

11

Lee LJ, Damato AL, Viswanathan AN. Clinical outcomes following 3D image-guided brachytherapy for vaginal recurrence of endometrial cancer. Gynecol Oncol. 2013;131(1):586-592.

12

Yoshida K, Yamazaki H, Kotsuma T, et al. Treatment results of image-guided high-dose-rate interstitial brachytherapy for pelvic recurrence of uterine cancer. Brachytherapy. 2015;14(4):440-448.

13

Fokdal L, Ørtoft G, Hansen ES, et al. Toward four-dimensional image-guided adaptive brachytherapy in locally recurrent endometrial cancer. Brachytherapy. 2014;13(6):554-561.

14

Conlon N, Leitao MM, Abu-Rustum NR, Soslow RA. Grading uterine endometrioid carcinoma: a proposal that binary is best. Am J Surg Pathol. 2014;38(12):1583-1587.

15
Brenda J, Zaino R. Gynecologic Oncology Group Pathology Manual. 1994.
16

Nout RA, Smit VTHBM, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2):an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816-823.

17

Pötter R, Tanderup K, Kirisits C, et al. The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9: 48-60.

18

Belliveau JG, Thind K, Banerjee R, et al. The impact of inter-fraction changes for perineal template-based interstitial gynecologic brachytherapy implants. J Contemp Brachytherapy. 2019;11(2):122-127.

19
Hoskin P, Nout R, Haie Medler C, VanLimbergen E, Poetter R. The GECEstro Handbook of Brachytherapy: Part II Clinical Practice. GEC ESTRO; 2016.
20

Murofushi KN, Tanaka R, Ohkawa A, Numajiri H, Okumura T, Sakurai H. Outcomes and dose-volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery. Clin Exp Obstet Gynecol. 2021;48: 601.

21

Baek S, Isohashi F, Yamaguchi H, et al. Salvage high-dose-rate brachytherapy for isolated vaginal recurrence of endometrial cancer. Brachytherapy. 2016;15(6):812-816.

22

Arden JD, Gruner MF, Vu CC, et al. Outcomes after salvage radiation therapy for recurrent endometrial cancer in patients with no prior adjuvant therapy: an institutional review. Adv Radiat Oncol. 2020;5(6):1240-1247.

23

Sekii S, Murakami N, Kato T, et al. Outcomes of salvage high-dose-rate brachytherapy with or without external beam radiotherapy for isolated vaginal recurrence of endometrial cancer. J Contemp Brachytherapy. 2017;9: 209-215.

24

Kotsuma T, Yoshida K, Yamazaki H, et al. Preliminary results of magnetic resonance imaging-aided high-dose-rate interstitial brachytherapy for recurrent uterine carcinoma after curative surgery. J Radiat Res. 2011;52(3):329-334.

25

Vargo JA, Kim H, Houser CJ, et al. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification. Radiother Oncol. 2014;113(1):126-131.

26

Kamrava M, Alrashidi SM, Leung E. Interstitial brachytherapy for gynecologic malignancies: complications, toxicities, and management. Brachytherapy. 2021;20(5):995-1004.

27

Glaser SM, Mohindra P, Mahantshetty U, Beriwal S. Complications of intracavitary brachytherapy for gynecologic cancers and their management: a comprehensive review. Brachytherapy. 2021;20(5):984-994.

28

Petignat P, Jolicoeur M, Alobaid A, et al. Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecol Oncol. 2006;101(3):445-449.

29

Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol. 2003;56(5):1366-1372.

Precision Radiation Oncology
Pages 45-50
Cite this article:
Waheed A, Banerjee R, Meyer T, et al. Clinical outcomes after salvage external beam radiotherapy combined with interstitial brachytherapy for locally advanced, recurrent endometrial cancer. Precision Radiation Oncology, 2023, 7(1): 45-50. https://doi.org/10.1002/pro6.1185

450

Views

1

Crossref

1

Scopus

Altmetrics

Received: 14 November 2022
Revised: 07 December 2022
Accepted: 29 December 2022
Published: 24 January 2023
© 2023 The Authors. Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Return